New anti-HIV agents and targets

Medicinal Research Reviews

Volumn 22, Issue 6, 2002, Pages 531-565

  De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

CCR5 (HIV); CXCR4 (HIV); Fusion (HIV); Human immunodeficiency virus (HIV); Integrase (HIV); Protease (HIV); Reverse transcriptase (HIV); Transcription (HIV)

Indexed keywords

1,1' [1,4 PHENYLENEBIS(METHYLENE)]BIS(1,4,8,11 TETRAAZACYCLOTETRADECANE); AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CXCR4; DELAVIRDINE; EFAVIRENZ; EMIVIRINE; EMTRICITABINE; ENFUVIRTIDE; FLAVOPIRIDOL; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; INDINAVIR; INTEGRASE; LOPINAVIR; MOZENAVIR; N [4 [[[6,7 DIHYDRO 2 (4 METHYLPHENYL) 5H BENZOCYCLOHEPTEN 8 YL]CARBONYL]AMINO]BENZYL] N,N DIMETHYL 2H TETRAHYDROPYRAN 4 AMINIUM CHLORIDE; NELFINAVIR; NEVIRAPINE; PHOSPHORAMIDIC ACID DERIVATIVE; PROTEINASE INHIBITOR; QUINOLONE DERIVATIVE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; T 1249; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CELL FUSION; DRUG BINDING SITE; DRUG TARGETING; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; REVIEW; TRANSCRIPTION REGULATION; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS NUCLEOCAPSID; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTI-HIV AGENTS; BINDING SITES; CAPSID; CAPSID PROTEINS; DRUG RESISTANCE, MULTIPLE, VIRAL; GENE PRODUCTS, GAG; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INTEGRASE INHIBITORS; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MOLECULAR SEQUENCE DATA; RECEPTORS, HIV; REVERSE TRANSCRIPTASE INHIBITORS; TRANSCRIPTION, GENETIC; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 0036846898     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.10021     Document Type: Review

References (187)

1. Tavel JA, Miller KD, Masur H. Guide to major clinical trials of antiretroviral therapy in human immunodeficiency virus-infected patients: Protease inhibitors, non-nucleoside reverse transcriptase inhibitors, and nucleotide reverse transcriptase inhibitors. Clin Infect Dis 1999;28:643-676.
2. + T cells. Science 1999;286:1353-1357.
3. http:/www.iasusa.org/resistance_mutations/index.html
4. Santhosh KC, Paul GC, De Clercq E, Pannecouque C, Witvrouw M, Loftus TL, Turpin JA, Buckheit RW, Jr., Cushman M. Correlation of anti-HIV activity with anion spacing in a series of cosalane analogues with extended polycarboxylate pharmacophores. J Med Chem 2001;44:703-714.
5. Witvrouw M, De Clercq E. Sulfated polysaccharides extracted from sea algea as potential antiviral drugs. Gen Pharmacol 1997;29:497-511.
6. Gallaher WR, Ball JM, Garry RF, Martin-Amedee AM, Montelaro RC. A general model for the surface glycoproteins of HIV and other retroviruses. AIDS Res Hum Retroviruses 1995;11:191-202.
7. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, Zhao L, Olson W, Kwong PD, Sattentau QJ. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000;74:1948-1960.
8. Shukla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG. A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus 1 entry. Cell 1999;99:13-22.
9. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 1997;3:866-871.
10. Su CM, Liao CL, Lee YL, Lin YL. Highly sulfated forms of heparin sulfate are involved in Japanese encephalitis virus infection. Virology 2001;286:206-215.
11. Lüscher-Mattli M. Polyanions - A lost chance in the fight against HIV and other virus diseases? Antiviral Chem Chemother 2000;11:249-259.
12. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, Gulakowski RJ, Wu L, Rivera MI, Laurencot CM, Currens MJ, Cardellina JH, II Buckheit RW, Jr., Nara PL, Pannell LK, Sowder RC, II Henderson LE. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: Potential applications to microbicide development. Antimicrob Agents Chemother 1997;41:1521-1530.
13. Mori T, Boyd MR. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother 2001;45:664-672.
14. Herold BC, Bourne N, Marcellino D, Kirkpatrick R, Strauss DM, Zaneveld LJ, Waller DP, Anderson RA, Chany CJ, Barham BJ, Stanberry LR, Cooper MD. Poly(sodium 4-styrene sulfonate): An effective candidate topical antimicrobial for the prevention of sexually transmitted diseases. J Infect Dis 2000;181:770-773.
15. Allaway GP, Davis-Bruno KL, Beaudry GA, Garcia EB, Wong EL, Ryder AM, Hasel KW, Gauduin MC, Koup RA, McDougal JS. Expression and characterization of CD4-IgG2, a novel heterotetramer that neutralizes primary HIV type 1 isolates. AIDS Res Hum Retroviruses 1995;11:533-539.
16. Zhu P, Olson WC, Roux KH. Structural flexibility and functional valence of CD4-IgG2 (PRO 542): Potential for cross-linking human immunodeficiency virus type 1 envelope spikes. J Virol 2001;75:6682-6686.
17. Nagashima KA, Thompson DA, Rosenfield SI, Maddon PJ, Dragic T, Olson WC. Human immunodeficiency virus type 1 entry inhibitors PRO 542 and T-20 are potently synergistic in blocking viruscell and cell-cell fusion. J Infect Dis 2001;183:1121-1125.
18. Jacobson JM, Lowy I, Fletcher CV, O'Neill TJ, Tran DN, Ketas TJ, Trkola A, Klotman ME, Maddon PJ, Olson WC, Israel RJ. Single-dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV-infected adults. J Infect Dis 2000;182:326-329.
19. Sastry KJ, Nehete P, Fantini J. Novel antiviral strategy targeting viral entry at a post-CD4 binding step common to infection by diverse HIV-1 strains. Fifteenth International Conference on Antiviral Research, Prague, Czech Republic, 17-21 March 2002. Antiviral Res 2002:53p, A35, no. 2.
20. Berson JF, Long D, Doranz BJ, Rucker J, Jirik FR, Doms RW. A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains. J Virol 1996;70:6288-6295.
21. Doranz BJ, Lu ZH, Rucker J, Zhang TY, Sharron M, Cen YH, Wang ZX, Guo HH, Du JG, Accavitti MA, Doms RW, Peiper SC. Two distinct CCR5 domains can mediate coreceptor usage by human immunodeficiency virus type 1. J Virol 1997;71:6305-6314.
22. Menten P, Struyf S, Schutyser E, Wuyts A, De Clercq E, Schols D, Proost P, Van Damme J. The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1-inhibiting chemokine. J Clin Invest 1999;104:R1-R5.
23. Nibbs RJ, Yang J, Landau NR, Mao JH, Graham GJ. LD78β, a non-allelic variant of human MIP-1α (LD78α), has enhanced receptor interactions and potent HIV suppressive activity. J Biol Chem 1999;274:17478-17483.
24. Aquaro S, Menten P, Struyf S, Proost P, Van Damme J, De Clercq E, Schols D. The LD78β isoform of MIP-1α is the most potent CC-chemokine in inhibiting CCR5-dependent human immunodeficiency virus type 1 replication in human macrophages. J Virol 2001;75:4402-4406.
25. Baba M, Nishimura O, Kanzaki N, Okamoto M, Sawada H, Iizawa Y, Shiraishi M, Aramaki Y, Okonogi K, Ogawa Y, Meguro K, Fujino M. A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. Proc Natl Acad Sci USA 1999;96:5698-5703.
26. Dragic T, Trkola A, Thompson DA, Cormier EG, Kajumo FA, Maxwell E, Lin SW, Ying W, Smith SO, Sakmar TP, Moore JP. A binding pocket for a small molecule inhibitor of HIV-1 entry within the transmembrane helices of CCR5. Proc Natl Acad Sci USA 2000;97:5639-5644.
27. Shiraishi M, Aramaki Y, Seto M, Imoto H, Nishikawa Y, Kanzaki N, Okamoto M, Sawada H, Nishimura O, Baba M, Fujino M. Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: Synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety. J Med Chem 2000;43:2049-2063.
28. Palani A, Shapiro S, Clader JW, Greenlee WJ, Cox K, Strizki J, Endres M, Baroudy BM. Discovery of 4-[(Z)-(4-bromophenyl)-(ethoxyimino)methyl]-1′-[(2, 4-dimethyl-3-pyridinyl)carbonyl]-4′-methyl-1,4′-bipiperidine N-oxide (SCH 351125): An orally bioavailable human CCR5 antagonist for the treatment of HIV infection. J Med Chem 2001;44:3339-3342.
29. Tagat JR, Steensma RW, McCombie SW, Nazareno DV, Lin SI, Neusta Wojcik L, Murray MG, Vantuno N, Baroudy BM, Strizki JM. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. II. Discovery of 1-[(2,4-dimethyl-3-pyridinyl)carbonyl]-4-methyl-4- [3(S)-methyl-4-[1(S)-[4-trifluoromethyl) phenyl]ethyl]-1-piperazinyl]-piperidine N1-oxide (Sch-350634), an orally bioavailable, potent CCR5 antagonist. J Med Chem 2001;44:3343-3346.
30. Strizki JM, Xu S, Wagner NE, Wojcik L, Liu J, Hou Y, Endres M, Palani A, Shapiro S, Clader JW, Greenlee WJ, Tagat JR, McCombie S, Cox K, Fawzi AB, Chou CC, Pugliese-Sivo C, Davies L, Moreno ME, Ho DD, Trkola A, Stoddart CA, Moore JP, Reyes GR, Baroudy BM. SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:12718-12723.
31. Reynes J, Rouzier R, Kanouni T, Baillat V, Baroudy B, Keung A, Hogan C, Markowitz M, Laughlin M. SCH C: Safety and antiviral effects of a CCR5 receptor antagonist in HIV-1 infected subjects. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 24-28 February 2002. Abstracts, 53p, no. 1.
32. Trkola A, Kuhmann SE, Strizki JM, Maxwell E, Ketas T, Morgan T, Pugach P, Xu S, Wojcik L, Tagat J, Palani A, Shapiro S, Clader JW, McCombie S, Reyes GR, Baroudy BM, Moore JP. HIV-1 escape from a small molecule, CCR5-specific entry inhibitor does not involve CXCR4 use. Proc Natl Acad Sci USA 2002;99:395-400.
33. Schols D, Struyf S, Van Damme J, Esté JA, Henson G, De Clercq E. Inhibition of T-tropic HIV strains by selective antagonization of the chemokine receptor CXCR4. J Exp Med 1997;186:1383-1388.
34. Murakami T, Nakajima T, Koyanagi Y, Tachibana K, Fujii N, Tamamura H, Yoshida N, Waki M, Matsumoto A, Yoshie O, Kishimoto T, Yamamoto N, Nagasawa T. A small molecule CXCR4 inhibitor that blocks T cell line-tropic HIV-1 infection. J Exp Med 1997;186:1389-1393.
35. Doranz BJ, Grovit-Ferbas K, Sharron MP, Mao SH, Goetz MB, Daar ES, Doms RW, O'Brien WA. A small-molecule inhibitor directed against the chemokine receptor CXCR4 prevents its use as an HIV-1 coreceptor. J Exp Med 1997;186:1395-1400.
36. De Clercq E. Inhibition of HIV infection by bicyclams, highly potent and specific CXCR4 antagonists. Mol Pharmacol 2000;57:833-839.
37. Bridger GJ, Skerlj RT, Padmanabhan S, Martellucci SA, Henson GW, Struyf S, Witvrouw M, Schols D, De Clercq E. Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4. J Med Chem 1999;42:3971-3981.
38. De Clercq E, Yamamoto N, Pauwels R, Baba M, Schols D, Nakashima H, Balzarini J, Debyser Z, Murrer BA, Schwartz D, Thornton D, Bridger G, Fricker S, Henson G, Abrams M, Picker D. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event. Proc Natl Acad Sci USA 1992;89:5286-5290.
39. De Clercq E, Yamamoto N, Pauwels R, Balzarini J, Witvrouw M, De Vreese K, Debyser Z, Rosenwirth B, Peichl P, Datema R, Thornton D, Skerlj R, Gaul F, Padmanabhan S, Bridger G, Henson G, Abrams M. Highly potent and selective inhibition of human immunodeficiency virus by the bicyclam derivative JM3100. Antimicrob Agents Chemother 1994;38:668-674.
40. Schols D, Esté JA, Henson G, De Clercq E. Bicyclams, a class of potent anti-HIV agents, are targeted at the HIV coreceptor fusin/CXCR-4. Antiviral Res 1997;35:147-156.
41. Donzella GA, Schols D, Lin SW, Esté JA, Nagashima KA, Maddon PJ, Allaway GP, Sakmar TP, Henson G, De Clercq D, Moore JP. AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor. Nat Med 1998;4:72-77.
42. Labrosse B, Brelot A, Heveker N, Sol N, Schols D, De Clercq E, Alizon M. Determinants for sensitivity of human immunodeficiency virus coreceptor CXCR4 to the bicyclam AMD3100. J Virol 1998;72:6381-6388.
43. Hatse S, Princen K, Gerlach LO, Bridger G, Henson G, De Clercq E, Schwartz TW, Schols D. Mutation of Asp(171) and Asp(262) of the chemokine receptor CXCR4 impairs its coreceptor function for human immunodeficiency virus-1 entry and abrogates the antagonistic activity of AMD3100. Mol Pharmacol 2001;60:164-173.
44. Hatse S, Princen K, Bridger G, Skerlj R, Henson G, De Clercq E, Schols D. A specific CXCR4 antagonist with potent anti-HIV activity. Fifteenth International Conference on Antiviral Research, Prague, Czech Republic, 17-21 March 2002. Antiviral Res 2002:53 p A36, no. 5.
45. Esté JA, Cabrera C, Blanco J, Gutierrez A, Bridger G, Henson G, Clotet B, Schols D, De Clercq E. Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4. J Virol 1999;73:5577-5585.
46. Datema R, Rabin L, Hincenbergs M, Moreno MB, Warren S, Linquist V, Rosenwirth B, Seifert J, McCune JM. Antiviral efficacy in vivo of the anti-human immunodeficiency virus bicyclam SDZ SID 791 (JM 3100), an inhibitor of infectious cell entry. Antimicrob Agents Chemother 1996;40:750-754.
47. Hendrix CW, Flexner C, MacFarland RT, Giandomenico C, Fuchs EJ, Redpath E, Bridger G, Henson GW. Pharmacokinetics and safety of AMD3100, a novel antagonist of the CXCR-4 chemokine receptor, in human volunteers. Antimicrob Agents Chemother 2000;44:1667-1673.
48. Schols D, Claes S, De Clercq E, Hendrix C, Bridger G, Calandra G, Henson GW, Fransen S, Huang W, Whitcomb JM, Petropoulos CJ & AMD-3100 HIV Study Group. AMD-3100, a CXCR4 antagonist, reduced HIV viral load and X4 virus levels in humans. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 24-28 February 2002. Abstracts, 53p, no. 2.
49. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T, Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verastegui E, Zlotnik A. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001;410:50-56.
50. Matthys P, Hatse S, Vermeire K, Wuyts A, Bridger G, Henson GW, De Clercq E, Billiau A, Schols D. AMD3100, a potent and specific antagonist of the stromal cell-derived factor-1 chemokine receptor CXCR4, inhibits autoimmune joint inflammation in IFN-gamma receptor-deficient mice. J Immunol 2001;167:4686-4692.
51. Sodroski JG. HIV-1 entry inhibitors in the side pocket. Cell 1999;99:243-246.
52. Wild CT, Shugars DC, Greenwell TK, McDanal CB, Matthews TJ. Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci USA 1994;91:9770-9774.
53. Kilby JM, Hopkins S, Venetta SM, DiMassimo B, Cloud GA, Lee JY, Alldredge L, Hunter E, Lambert D, Bolognesi D, Matthews T, Johnson MR, Nowak MA, Shaw GM, Saag MS. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998;4:1302-1307.
54. Conway B. T-1249 trimeris. Curr Opin Anti-Infect Invest Drugs 2000;2:317-322.
55. Mayaux JF, Bousseau A, Pauwels R, Huet T, Henin Y, Dereu N, Evers M, Soler F, Poujade C, De Clercq E, Le Pecq JB. Triterpene derivatives that block entry of human immunodeficiency virus type 1 into cells. Proc Natl Acad Sci USA 1994;91:3564-3568.
56. Labrosse B, Pleskoff O, Sol N, Jones C, Henin Y, Alizon M. Resistance to a drug blocking human immunodeficiency virus type 1 entry (RPR103611) is conferred by mutations in gp41. J Virol 1997;71:8230-8236.
57. Labrosse B, Treboute C, Alizon M. Sensitivity to a nonpeptide compound (RPR103611) blocking human immunodeficiency virus type 1 Env-mediated fusion depends on sequence and accessibility of the gp41 loop region. J Virol 2000;74:2142-2150.
58. Holz-Smith SL, Sun IC, Jin L, Matthews TJ, Lee KH, Chen CH. Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. Antimicrob Agents Chemother 2001;45:60-66.
59. Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, Goto T, Sano K, Nakashima H. Antihuman immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 2001;45:1225-1230.
60. Rice WG, Turpin JA, Arthur LO, Henderson LE. Highly conserved retroviral zinc fingers as targets for HIV-1 therapeutic management. Int Antiviral News 1995;3:87-89.
61. Witviouw M, Balzarini J, Pannecouque C, Jhaumeer-Laulloo S, Esté JA, Schols D, Cherepanov P, Schmit J-C, Debyser Z, Vandamme AM, Desmyter J, Ramadas SR, De Clercq E. SRR-SB3, a disulfide-containing macrolide that inhibits a late stage of the replicative cycle of human immunodeficiency virus. Antimicrob Agents Chemother 1997;41:262-268.
62. Rice WG, Baker DC, Schaeffer CA, Graham L, Bu M, Terpening S, Clanton D, Schultz R, Bader JP, Buckheit RW, Jr., Field L, Singh PK, Turpin JA. Inhibition of multiple phases of human immunodeficiency virus type 1 replication by a dithiane compound that attacks the conserved zinc fingers of retroviral nucleocapsid proteins. Antimicrob Agents Chemother 1997;41:419-426.
63. Vandevelde M, Witvrouw M, Schmit J-C, Sprecher S, De Clercq E, Tassignon JP. ADA, a potential anti-HIV drug. AIDS Res Hum Retroviruses 1996;12:567-568.
64. Rice WG, Turpin JA, Huang M, Clanton D, Buckheit RW, Jr., Covell DG, Wallqvist A, McDonnell NB, DeGuzman RN, Summers MF, Zalkow L, Bader JP, Haugwitz RD, Sausville EA. Azodicarbonamide inhibits HIV-1 replication by targeting the nucleocapsid protein. Nat Med 1997;3:341-345.
65. Turpin JA, Schaeffer CA, Terpening SJ, Graham L, Bu M, Rice WG. Reverse transcription of human immunodeficiency virus type 1 is blocked by retroviral zinc finger inhibitors. Antiviral Chem Chemother 1997;8:60-69.
66. Berthoux L, Péchoux C, Darlix J-L. Multiple effects of an anti-human immunodeficiency virus nucleocapsid inhibitor on virus morphology and replication. J Virol 1999;73:10000-10009.
67. Huang M, Maynard A, Turpin JA, Graham L, Janini GM, Covell DG, Rice WG. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. J Med Chem 1998;41:1371-1381.
68. Goebel F-D, Hemmer R, Schmit J-C, Bogner JR, De Clercq E, Witvrouw M, Pannecouque C, Valeyev R, Vandevelde M, Margery H, Tassignon J-P. Phase I/II dose escalation and randomized withdrawal study with add-on azodicarbonamide in patients failing on current antiretroviral therapy. AIDS 2001;15:33-45.
69. Tassignon J, Ismaili J, Le Moine A, Van Laethem F, Leo O, Vandevelde M, Goldman M. Azodicarbonamide inhibits T-cell responses in vitro and in vivo. Nat Med 1999;5:947-950.
70. De Clercq E. Toward improved anti-HIV chemotherapy: Therapeutic strategies for intervention with HIV infections. J Med Chem 1995;38:2491-2517.
71. Girard P-M, Pegram PS, Diquet B, Anderson R, Raffi F, Tubiana R, Sereni D, Boerner D. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: Pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr 2000;23:227-235.
72. Naesens L, Snoeck R, Andrei G, Balzarini J, Neyts J, De Clercq E. HPMPC (cidofovir), PMEA (adefovir) and related acyclic nucleoside phosphonate analogues: A review of their pharmacology and clinical potential in the treatment of viral infections. Antiviral Chem Chemother 1997;8:1-23.
73. Barditch-Crovo P, Deeks SG, Collier A, Safrin S, Coakley DF, Miller M, Kearney BP, Coleman RL, Lamy PD, Kahn JO, McGowan I, Lietman PS. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2001;45:2733-2739.
74. Smith MS, Foresman L, Lopez GJ, Tsay J, Wodarz D, Lifson JD, Page A, Wang C, Li Z, Adany I, Buch S, Bischofberger N, Narayan O. Lasting effects of transient postinoculation tenofovir [9-R-(2-phosphonomethoxypropyl)adenine] treatment on SHIV (KU2) infection of rhesus macaques. Virology 2000;277:306-315.
75. Louie M, Hogan C, Hurley A, Captan B, Flaherty J, Lamy P, Balagtas A, Coakley D, Chung C, Ho DD, Markowitz M. Determining the relative efficacy of tenofovir DF using frequent measurements of HIV-1 RNA during a short course of monotherapy in antiretroviral drug naïve individuals. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 24-28 February 2002. Abstracts, 54p, no. 3.
76. Deeks SG, Barditch-Crovo P, Lietman PS, Hwang F, Cundy KC, Rooney JF, Hellmann NS, Safrin S, Kahn JO. Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphono-methoxy)propyl]adenine, a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998;42:2380-2384.
77. McColl D, Margot N, Miller MD. Analyses of viral and cellular resistance in HIV-1 infected patients adding tenofovir disoproxil fumarate therapy to stable background regimens. Fifteenth International Conference on Antiviral Research, Prague, Czech Republic, 17-21 March 2002. Antiviral Res 2002:53p, A37, no. 9.
78. de Muys JM, Gourdeau H, Nguyen-Ba N, Taylor DL, Ahmed PS, Mansour T, Locas C, Richard N, Wainberg MA, Rando RF. Anti-human immunodeficiency virus type 1 activity, intracellular metabolism, and pharmacokinetic evaluation of 2′-deoxy-3′-oxa-4′-thiocytidine. Antimicrob Agents Chemother 1999;43:1835-1844.
79. Gu Z, Wainberg MA, Nguyen-Ba N, L'Heureux L, de Muys JM, Bowlin TL, Rando RF. Mechanism of action and in vitro activity of 1′,3′-dioxolanylpurine nucleoside analogues against sensitive and drug-resistant human immunodeficiency virus type 1 variants. Antimicrob Agents Chemother 1999;43:2376-2382.
80. Uchida H, Kodama EN, Yoshimura K, Maeda Y, Kosalaraksa P, Maroun V, Qiu YL, Zemlicka J, Mitsuya H. In vitro anti-human immunodeficiency virus activities of Z- and E-methylenecyclopropane nucleoside analogues and their phosphoro-L-alaninate diesters. Antimicrob Agents Chemother 1999;43:1487-1490.
81. Yoshimura K, Feldman R, Kodama E, Kavlick MF, Qiu YL, Zemlicka J, Mitsuya H. In vitro induction of human immunodeficiency virus type 1 variants resistant to phosphoralaninate prodrugs of Z-methylenecyclopropane nucleoside analogues. Antimicrob Agents Chemother 1999;43:2479-2483.
82. Kodama EI, Kohgo S, Kitano K, Machida H, Gatanaga H, Shigeta S, Matsuoka M, Ohrui H, Mitsuya H. 4′-Ethynyl nucleoside analogs: Potent inhibitors of multidrug-resistant human immunodeficiency virus variants in vitro. Antimicrob Agents Chemother 2001;45:1539-1546.
83. Rousseau FS, Kahn JO, Thompson M, Mildvan D, Shepp D, Sommadossi JP, Delehanty J, Simpson JN, Wang LH, Quinn JB, Wakeford C, van der Horst C. Prototype trial design for rapid dose selection of antiretroviral drugs: An example using emtricitabine (Coviracil). Antimicrob Agents Chemother 2001;48:507-513.
84. Molina JM, Ferchal F, Rancinan C, Raffi F, Rozenbaum W, Sereni D, Morlat P, Journot V, Decazes JM, Chene G. Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients. J Infect Dis 2000;182:599-602.
85. Richman DD. Antiretroviral activity of emtricitabine, a potent nucleoside reverse transcriptase inhibitor. Antiviral Ther 2001;6:83-88.
86. Furman PA, Jeffrey J, Kiefer LL, Feng JY, Anderson KS, Borroto-Esoda K, Hill E, Copeland WC, Chu CK, Sommadossi JP, Liberman I, Schinazi RF, Painter GR. Mechanism of action of 1-β-D-2,6-diaminopurine dioxolane, a prodrug of the human immunodeficiency virus type 1 inhibitor 1-β-D-dioxolane guanosine. Antimicrob Agents Chemother 2001;45:158-165.
87. Corbett AH, Rublein JC. DAPD (Emory University/Triangle Pharmaceuticals/Abbott Laboratories). Curr Opin Invest Drugs 2001;2:348-353.
88. Painter GR, St Claire R, Feng J, Borroto-Esoda K. Anabolic profile of the dioxolane nucleoside analogue DXG in human PBMC; reversal of resistance by boosting 5′-triphosphate levels. Fifteenth International Conference on Antiviral Research, Prague, Czech Republic, 17-21 March 2002. Antiviral Res 2002:53p, A37, no. 7.
89. Lee K, Gulick RM. New drugs for the treatment of HIV infection. Curr Infect Dis Rep 2001;3:193-200.
90. Stoddart CA, Moreno ME, Linquist-Stepps VD, Bare C, Bogan MR, Gobbi A, Buckheit RW, Jr., Bedard J, Rando RF, McCune JM. Antiviral activity of 2′-deoxy-3′-oxa-4′-thiocytidine (BCH-10652) against lamivudine-resistant human immunodeficiency virus type 1 in SCID-hu Thy/Liv mice. Antimicrob Agents Chemother 2000;44:783-786.
91. Taylor DL, Ahmed PS, Tyms AS, Wood LJ, Kelly LA, Chambers P, Clarke J, Bedard J, Bowlin TL, Rando RF. Drug resistance and drug combination features of the human immunodeficiency virus inhibitor, BCH-10652 [(+/-)-2′-deoxy-3′-oxa-4′-thiocytidine, dOTC]. Antiviral Chem Chemother 2000;11:291-301.
92. Kodama E, Matsuoka M, Ohrui H, Mitsuya H. 4′-Ethynyl nucleoside analogues: Potent inhibitors active against multidrug-resistant HIV variants. Int Antiviral News 2001;9:128-129.
93. Perigaud C, Aubertin AM, Benzaria S, Pelicano H, Girardet JL, Maury G, Gosselin G, Kirn A, Imbach JL. Equal inhibition of the replication of human immunodeficiency virus in human T-cell culture by ddA bis(SATE)phosphotriester and 3′-azido-2′,3′-dideoxythymidine. Biochem Pharmacol 1994;48:11-14.
94. McGuigan C, Tsang HW, Cahard D, Turner K, Velazquez S, Salgado A, Bidois L, Naesens, L, De Clercq E, Balzarini J. Phosphoramidate derivatives of d4T as inhibitors of HIV: The effect of amino acid variation. Antiviral Res 1997;35:195-204.
95. Siddiqui AQ, Ballatore C, McGuigan C, De Clercq E, Balzarini J. The presence of substituents on the aryl moiety of the aryl phosphoramidate derivative of d4T enhances anti-HIV efficacy in cell culture: A structure-activity relationship. J Med Chem 1999;42:393-399.
96. Siddiqui AQ, McGuigan C, Ballatore C, Zuccotto F, Gilbert IH, De Clercq E, Balzarini J. Design and synthesis of lipophilic phosphoramidate d4T-MP prodrugs expressing high potency against HIV in cell culture: Structural determinants for in vitro activity and QSAR. J Med Chem 1999;42:4122-4128.
97. Saboulard D, Naesens L, Cahard D, Salgado A, Pathirana R, Velazquez S, McGuigan C, De Clercq E, Balzarini J. Characterization of the activation pathway of phosphoramidate triester prodrugs of stavudine and zidovudine. Mol Pharmacol 1999;56:693-704.
98. Aquaro S, Wedgwood O, Yarnold C, Cahard D, Pathirana R, McGuigan C, Calio R, De Clercq E, Balzarini J, Perno CF. Activities of masked 2′,3′-dideoxynucleoside monophosphate derivatives against human immunodeficiency virus in resting macrophages. Antimicrob Agents Chemother 2000;44:173-177.
99. Meier C, Lorey M, De Clercq E, Balzarini J. Cyclic saligenyl phosphotriesters of 2′,3′-dideoxy-2′,3′-didehydrothymidine (d4T)-A new pro-nucleotide approach. Bioorg Med Chem Lett 1997;7:99-104.
100. Meier C, Knispel T, De Clercq E, Balzarini J. ADA-Bypass by lipophilic cycloSa1-ddAMP pronucleotides-A second example of the efficiency of the cycloSa1-concept. Bioorg Med Chem Lett 1997;7:1577-1582.
101. Meier C, Lorey M, De Clercq E, Balzarini J. CycloSa1-2′,3′-dideoxy-2′,3′-didehydrothymidine monophosphate (cycloSa1-d4TMP): Synthesis and antiviral evaluation of a new d4TMP delivery system. J Med Chem 1998;41:1417-1427.
102. Meier C, Knispel T, De Clercq E, Balzarini J. CycloSa1-pronucleotides of 2′,3′-dideoxyadenosine and 2′,3′-dideoxy-2′,3′-didehydroadenosine: Synthesis and antiviral evaluation of a highly efficient nucleotide delivery system. J Med Chem 1999;42:1604-1614.
103. Balzarini J, Aquaro S, Knispel T, Rampazzo C, Bianchi V, Perno CF, De Clercq E, Meier C. Cyclosaligenyl-2′,3′-didehydro-2′,3′-dideoxythymidine monophosphate: Efficient intracellular delivery of d4TMP. Mol Pharmacol 2000;58:928-935.
104. De Clercq E. The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Antiviral Res 1998;38:153-179.
105. Szczech GM, Furman P, Painter GR, Barry DW, Borroto-Esoda K, Grizzle TB, Blum MR, Sommadossi J, Endoh R, Niwa T, Yamamoto M, Moxham C. Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000;44:123-130.
106. Hopkins AL, Ren J, Tanaka H, Baba M, Okamoto M, Stuart DI, Stammers DK. Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. J Med Chem 1999;42:4500-4505.
107. Ren J, Esnouf RM, Hopkins AL, Warren J, Balzarini J, Stuart DI, Stammers DK. Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. Biochemistry 1998;37:14394-14403.
108. Deeks SG. International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001;26:S25-S33.
109. Borkow G, Arion D, Wainberg MA, Parniak MA. The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999;43:259-263.
110. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA, Parniak MA. Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. J Virol 1997;71:3023-3030.
111. Balzarini J, Naesens L, Verbeken E, Laga M, Van Damme L, Parniak M, Van Mellaert L, Anné J, De Clercq E. Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent AIDS 1998;12:1129-1138.
112. Witvrouw M, Arranz ME, Pannecouque C, De Clercq R, Jonckheere H, Schnut JC, Vandamme AM, Diaz JA, Ingate ST, Desmyter J, Esnouf R, Van Meervelt L, Vega S, Balzarini J, De Clercq E. 1,1,3-trioxo-2H,4H-thieno[3,4-e][1,2,4]thiadiazine (TTD) derivatives: A new class of nonnucleoside human immunodeficiency virus type 1 (HIV-1) reverse transcriptase inhibitors with anti-HIV-1 activity. Antimicrob Agents Chemother 1998;42:618-623.
113. Prince P, Moore K, Cass L, Dallow N, Jones A, Kleim J-P, Mutch P, St Clair M. GW420867X, a new nonnucleoside reverse transcriptase inhibitor (NNRTI)-Initial phase I evaluation. Abstracts of the 12th International Conference on Antiviral Research, Jerusalem, Israel, 21-25 March 1999. Antiviral Res 1999;41:A48.
114. Fujiwara T, Sato A, el-Farrash M, Miki S, Abe K, Isaka Y, Kodama M, Wu Y, Chen LB, Harada H, Sugimoto H, Hatanaka M, Hinuma Y. S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1998;42:1340-1345.
115. Ren J, Nichols C, Bird LE, Fujiwara T, Sugimoto H, Stuart DI, Stammers DK. Binding of the second generation non-nucleoside inhibitor S-1153 to HIV-1 reverse trancriptase involves extensive main chain hydrogen bonding. J Biol Chem 2000;275:14316-14320.
116. Brown WM. Capravirine. Curr Opin Anti-Infect Invest Drugs 2000;2:286-294.
117. Wishka DG, Graber DR, Kopta LA, Olmsted RA, Friis JM, Hosley JD, Adams WJ, Seest EP, Castle TM, Dolak LA, Keiser BJ, Yagi Y, Jeganathan A, Schlachter ST, Murphy MJ, Cleek GJ, Nugent RA, Poppe SM, Swaney SM, Han F, Watt W. White WL, Poel TJ, Thomas RC, Morris J. (-)-6-chloro-2-[(1-furo [2,3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor. J Med Chem 1998;41:1357-1360.
118. Mao C, Sudbeck EA, Venkatachalam TK, Uckun FM. Rational design of N-[2-(2,5-dimethoxyphenylethyl]-N′-[2-(5-bromopyridyl)]-thiourea (HI-236) as a potent non-nucleoside inhibitor of drug-resistant human immunodeficiency virus. Bioorg Med Chem Lett 1999;9:1593-1598.
119. Taylor DL, Ahmed PS, Chambers P, Tyms AS, Bedard J, Duchaine J, Falardeau G, Lavallee JF, Brown W, Rando RF, Bowlin T. Pyrido[1,2a]indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1. Antiviral Chem Chemother 1999;10:79-86.
120. Corbett JW, Ko SS, Rodgers JD, Jeffrey S, Bacheler LT, Klabe RM, Diamond S, Lai CM, Rabel SR, Saye JA, Adams SP, Trainor GL, Anderson PS, Erickson-Viitanen SK. Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrob Agents Chemother 1999;43:2893-2897.
121. Uckun FM, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Mao C, Venkatachalam TK. N′-[2-(2-thiophene)ethyl]-N′-[2-(5-bromopyridyl)] thiourea as a potent inhibitor of NNI-resistant and multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett 1999;9:3411-3416.
122. Uckun FM, Mao C, Pendergrass S, Maher D, Zhu D, Tuel-Ahlgren L, Venkatachalam TK. N-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-bromopyridyl)]-thiourea and N′-[2-(1-cyclohexenyl)ethyl]-N′-[2-(5-chloropyridyl)]-thiourea as potent inhibitors of multidrug-resistant human immunodeficiency virus-1. Bioorg Med Chem Lett 1999;9:2721-2726.
123. Högberg M, Sahlberg C, Engelhardt P, Noreen R, Kangasmetsa J, Johansson NG, Öberg B, Vrang L, Zhang H, Sahlberg BL, Unge T, Lövgren S, Fridborg K, Backbrö K. Urea-PETT compounds as a new class of HIV-1 reverse transcriptase inhibitors. 3. Synthesis and further structure-activity relationship studies of PETT analogues. J Med Chem 1999;42:4150-4160.
124. Casimiro-Garcia A, Micklatcher M, Turpin JA, Stup TL, Watson K, Buckheit RW, Cushman M. Novel modifications in the alkenyldiarylmethane (ADAM) series of non-nucleoside reverse transcriptase inhibitors. J Med Chem 1999;42:4861-4874.
125. Campiani G, Morelli E, Fabbrini M, Nacci V, Greco G, Novellino E, Ramunno A, Maga G, Spadari S, Caliendo G, Bergamini A, Faggioli E, Uccella I, Bolacchi F, Marini S, Coletta M, Nacca A, Caccia S. Pyrrolobenzoxazepinone derivatives as non-nucleoside HIV-1 RT inhibitors: Further structure-activity relationship studies and identification of more potent broad-spectrum HIV-1 RT inhibitors with antiviral activity. J Med Chem 1999;42:4462-4470.
126. Campiani G, Aiello F, Fabbrini M, Morelli E, Ramunno A, Armaroli S, Nacci V, Garofalo A, Greco G, Novellino E, Maga G, Spadari S, Bergamini A, Ventura L, Bongiovanni B, Capozzi M, Bolacchi F, Marini S, Coletta M, Guiso G, Caccia S. Quinoxalinylethylpyridylthioureas (QXPTs) as potent non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors. Further SAR studies and identification of a novel orally bioavailable hydrazine-based antiviral agent. J Med Chem 2001;44:305-315.
127. Buckheit RW, Jr., Watson K, Fliakas-Boltz V, Russell J, Loftus TL, Osterling MC, Turpin JA, Pallansch LA, White EL, Lee JW, Lee SH, Oh JW, Kwon HS, Chung SG, Cho EH. SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrob Agents Chemother 2001;45:393-400.
128. Andries K, de Béthune M-P, Kukla MJ, Azijn H, Lewi PJ, Janssen PAJ, Pauwels R. R165335-TMC125, a novel non nucleoside reverse transcriptase inhibitor (NNRTI) with nanomolar activity against NNRTI resistant HIV strains. Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17-20 September 2000, no. 1840.
129. Gazzard B, Pozniak A, Arasteh K, Staszewski S, Rozenbaum W, Yeni P, van't Klooster G, De Dier K, Peeters M, de Béthune MP, Graham N, Pauwels R. TMC125, a next-generation NNRTI, demonstrates high potency after 7 days therapy in treatment-experienced HIV-1-infected individuals with phenotypic NNRTI resistance. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 24-28 February 2002. Abstracts, 54p, no. 4.
130. Sankatsing S, Weverling G, van't Klooste G, Prins J, Lange J. TMCI25 monotherapy for 1 week results in a similar initial rate of decline of HIV-1 RNA as therapy with a 5-drug regimen. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 24-28 February 2002. Abstracts, 54p, no. 5.
131. Ruiz N, Nusrat R, Lauenroth-Mai E, Berger D, Walworth C, Bacheler LT, Ploughman L, Tsang P, Labriola D, Echols R, Levy R, and the DPC 083-203 Study Team. Study DPC 083-203, a phase II comparison of 100 and 200 mg once-daily DPC 083 and 2 NRTIs in patients failing a NNRTI-containing regimen. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 24-28 February 2002. Abstracts, 55p, no. 6.
132. Ruiz N, Nusrat R, Lazzarin A, Arasteh K, Goebel F-D, Audagnotto S, Rachlis A, Arribas J, Ploughman L, Fiske W, Labriola D, Levy R, Echols R, and the DPC 083-201 Study Team. Study DPC 083-201: A phase II double-blind (DB) comparison of 3 once-daily doses of the NNRTI DPC 083 vs. 600 mg efavirenz (EFV) in combination with 2 NRTIs in HIV antiretroviral (ARV) treatment naïve-patients. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 24-28 February 2002. Abstracts, 55p, no. 7.
133. Creagh T, Ruckle JL, Tolbert DT, Giltner J, Eiznhamer DA, Dutta B, Flavin MT, Xu ZQ. Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrob Agents Chemother 2001;45:1379-1386.
134. Tachedjian G, Orlova M, Sarafianos SG, Arnold E, Goff SP. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA 2001;98:7188-7193.
135. Pommier Y, Marchand C, Neamati N. Retroviral integrase inhibitors year 2000: Update and perspectives. Antiviral Res 2000;47:139-148.
136. Neamati N, Mazumder A, Sunder S, Owen JM, Tandon M, Lown JW, Pommier Y. Highly potent synthetic polyamides, bisdistamycins, and lexitropsins as inhibitors of human immunodeficiency virus type 1 integrase. Mol Pharmacol 1998;54:280-290.
137. Farnet CM, Wang B, Hansen M, Lipford JR, Zalkow L, Robinson WE, Jr., Siegel J, Bushman F. Human immunodeficiency virus type 1 cDNA integration: New aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob Agents Chemother 1998;42:2245-2253.
138. Neamati N, Turpin JA, Winslow HE, Christensen JL, Williamson K, Orr A, Rice WG, Pommier Y, Garofalo A, Brizzi A, Campiani G, Fiorini I, Nacci V. Thiazolothiazepine inhibitors of HIV-1 integrase. J Med Chem 1999;42:3334-3341.
139. Robinson WE, Jr., Reinecke MG, Abdel-Malek S, Jia Q, Chow SA. Inhibitors of HIV-1 replication that inhibit HIV integrase. Proc Natl Acad Sci USA 1996;93:6326-6331.
140. Robinson WE, Jr. L-chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitro anti-HIV-1 effect of zidovudine plus a protease inhibitor (AG1350). Antiviral Res 1998;39:101-111.
141. King PJ, Robinson WE, Jr. Resistance to the anti-human immunodeficiency virus type 1 compound L-chicoric acid results from a single mutation at amino acid 140 of integrase. J Virol 1998;72:8420-8424.
142. Mazumder A, Raghavan K, Weinstein J, Kohn KW, Pommier Y. Inhibition of human immunodeficiency virus type-1 integrase by curcumin. Biochem Pharmacol 1995;49:1165-1170.
143. Robinson WE, Jr., Cordeiro M, Abdel-Malek S, Jia Q, Chow SA, Reinecke MG, Mitchell WM. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: Inhibition of the core catalytic domain of human immunodeficiency virus integrase. Mol Pharmacol 1996;50:846-855.
144. Mazumder A, Neamati N, Sunder S, Schulz J, Pertz H, Eich E, Pommier Y. Curcumin analogs with altered potencies against HIV-1 integrase as probes for biochemical mechanisms of drug action. J Med Chem 1997;40:3057-3063.
145. McDougall B, King PJ, Wu BW, Hostomsky Z, Reinecke MG, Robinson WE, Jr. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother 1998;42:140-146.
146. Pluymers W, Neamati N, Pannecouque C, Fikkert V, Marchand C, Burke TR, Jr., Pommier Y, Schols D, De Clercq E, Debyser Z, Witvrouw M. Viral entry as the primary target for the anti-HIV activity of chicoric acid and its tetra-acetyl esters. Mol Pharmacol 2000;58:641-648.
147. Goldgur Y, Craigie R, Cohen GH, Fujiwara T, Yoshinaga T, Fujishita T, Sugimoto H, Endo T, Murai H, Davies DR. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: A platform for antiviral drug design. Proc Natl Acad Sci USA 1999;96:13040-13043.
148. Hazuda DJ, Felock P, Witmer M, Wolfe A, Stillmock K, Grobler JA, Espeseth A, Gabryelski L, Schleif W, Blau C, Miller MD. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287:646-650.
149. Wai JS, Egbertson MS, Payne LS, Fisher TE, Embrey MW, Tran LO, Melamed JY, Langford HM, Guare JP, Jr., Zhuang L, Grey VE, Vacca JP, Holloway MK, Naylor-Olsen AM, Hazuda DJ, Felock PJ, Wolfe AL, Stillmock KA, Schleif WA, Gabryelski LJ, Young SD. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells. J Med Chem 2000;43:4923-4926.
150. Witvrouw M, Fikkert V, Van Maele B, Pannecouque C, Neamati N, Burke TR, Jr., Pais G, De Clercq E, Debyser Z. Antiviral resistance to diketo acids is associated with the mutations T66I, L74M and S230R in the HIV-1 integrase gene. Fifteenth International Conference on Antiviral Research, Prague, Czech Republic, 17-21 March 2002. Antiviral Res 2002:53p, A48, no. 45.
151. Yoshinaga T, Sato A, Fujishita T, Fujiwara T. S-1360: In vitro activity of a new HIV-1 integrase inhibitor in clinical development. Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, Washington, USA, 24-28 February 2002. Abstracts, 55p, no. 8.
152. Daelemans D, Vandamme AM, De Clercq E. Human immunodeficiency virus gene regulation as a target for antiviral chemotherapy. Antiviral Chem Chemother 1999;10:1-14.
153. Watson K, Edwards RJ. HIV-1-trans-activating (Tat) protein: Both a target and a tool in therapeutic approaches. Biochem Pharmacol 1999;58:1521-1528.
154. Baba M, Okamoto M, Makino M, Kimura Y, Ikeuchi T, Sakaguchi T, Okamoto T. Potent and selective inhibition of human immunodeficiency virus type 1 transcription by piperazinyloxoquinoline derivatives. Antimicrob Agents Chemother 1997;41:1250-1255.
155. Baba M, Okamoto M, Kawamura M, Makino M, Higashida T, Takashi T, Kimura Y, Ikeuchi T, Tetsuka T, Okamoto T. Inhibition of human immunodeficiency virus type 1 replication and cytokine production by fluoroquinoline derivatives. Mol Pharmacol 1998;53:1097-1103.
156. Okamoto H, Cujec TP, Okamoto M, Peterlin BM, Baba M, Okamoto T. Inhibition of the RNA-dependent transactivation and replication of human immunodeficiency virus type 1 by a fluoroquinoline derivative K-37. Virology 2000;272:402-408.
157. Turpin JA, Buckheit RW, Jr., Derse D, Hollingshead M, Williamson K, Palamone C, Osterling MC, Hill SA, Graham L, Schaeffer CA, Bu M, Huang M, Cholody WM, Michejda CJ, Rice WG. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob Agents Chemother 1998;42:487-494.
158. Turpin JA, Kearney M, Ptak RG, Fliakas-Boltz V, Pallansch L, Michejda C, Cholody WC, Buckheit RW, Jr. Inhibition of HIV-1 replication by temacrazine is reversed by LTR mutations that increase the basal rate of viral transcript initiation. Abstracts of the 4th International Workshop on Drug Resistance & Treatment Strategies, Sitges, Spain, 12-16 June 2000, Antiviral Ther 2000;5(Suppl. 3):37, no. 50.
159. Kashanchi F, Sadaie MR, Brady JN. Inhibition of HIV-1 transcription and virus replication using soluble Tat peptide analogs. Virology 1997;227:431-438.
160. Choudhury I, Wang J, Rabson AB, Stein S, Pooyan S, Stein S, Leibowitz MJ. Inhibition of HIV-1 replication by a Tat RNA-binding domain peptide analog. J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:104-111.
161. Hamy F, Felder ER, Heizmann G, Lazdins J, Aboul-ela F, Varani G, Karn J, Klimkait T. An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc Natl Acad Sci USA 1997;94:3548-3553.
162. Daelemans D, Schols D, Witvrouw M, Pannecouque C, Hatse S, van Dooren S, Hamy F, Klimkait T, De Clercq E, Vandamme A-M. A second target for the peptoid Tat/transactivation response element inhibitor CGP64222: Inhibition of human immunodeficiency virus replication by blocking CXC-chemokine receptor 4-mediated virus entry. Mol Pharmacol 2000;57:116-124.
163. Ghezzi S, Noonan DM, Aluigi MG, Vallanti G, Cota M, Benelli R, Morini M, Reeves JD, Vicenzi E, Poli G, Albini A. Inhibition of CXCR4-dependent HIV-1 infection by extracellular HIV-1 Tat. Biochem Biophys Res Commun 2000;270:992-996.
164. Chao SH, Fujinaga K, Marion JE, Taube R, Sausville EA, Senderowicz AM, Peterlin BM, Price DH. Flavopiridol inhibits P-TEFb and blocks HIV-1 replication. J Biol Chem 2000;275:28345-28348.
165. Flexner C. HIV-protease inhibitors. N Engl J Med 1998;338:1281-1292.
166. Molla A, Granneman GR, Sun E, Kempf DJ. Recent developments in HIV protease inhibitor therapy. Antiviral Res 1998;39:1-23.
167. Murphy RL, Brun S, Hicks C, Eron JJ, Gulick R, King M, White AC, Jr., Benson C, Thompson M, Kessler HA, Hammer S, Bertz R, Hsu A, Japour A, Sun E. ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-Week results. AIDS 2001;15:F1-F9.
168. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Stewart K, Lal R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Norbeck DW. ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrob Agents Chemother 1998;42:3218-3224.
169. Alterman M, Bjorsne M, Muhlman A, Classon B, Kvarnstrom I, Danielson H, Markgren PO, Nillroth U, Unge T, Hallberg A, Samuelsson B. Design and synthesis of new potent C2-symmetric HIV-1 protease inhibitors. Use of L-mannaric acid as a peptidomimetic scaffold. J Med Chem 1998;41:3782-3792.
170. Muhlman A, Lindberg J, Classon B, Unge T, Hallberg A, Samuelsson B. Synthesis of novel, potent, diol-based HIV-1 protease inhibitors via intermolecular pinacol homocoupling of (2S)-2-benzyloxymethyl-4-phenylbutanal. J Med Chem 2001;44:3407-3416.
171. Thaisrivongs S, Tomich PK, Watenpaugh KD, Chong KT, Howe WJ, Yang CP, Strohbach JW, Turner SR, McGrath JP, Bohanon MJ, Lynn JC, Mulichak AM, Spinelli PA, Hinshaw RR, Pagano PJ, Moon JB, Ruwart MJ, Wilkinson KF, Rush BD, Zipp GL, Dalga RJ, Schwende FJ, Howard GM, Padbury GE, Toth LN, Zhao Z, Koeplinger KA, Kakuk TJ, Cole SL, Zaya RM, Piper RC, Jeffrey P. Structure-based design of HIV protease inhibitors: 4-Hydroxycoumarins and 4-hydroxy-2-pyrones as non-peptidic inhibitors. J Med Chem 1994;37:3200-3204.
172. Skulnick HI, Johnson PD, Howe WJ, Tomich PK, Chong K-T, Watenpaugh KD, Janakiraman MN, Dolak LA, McGrath JP, Lynn JC, Horng M-M, Hinshaw RR, Zipp GL, Ruwart MJ, Schwende FJ, Zhong W-Z, Padbury GE, Dalga RJ, Shiou L, Possert PL, Rush BD, Wilkinson KF, Howard GM, Toth LN, Williams MG, Kakuk TJ, Cole SL, Zaya RM, Lovasz KD, Morris JK, Romines KR, Thaisrivongs S, Aristoff PA. Structure-based design of sulfonamide-substituted non-peptidic HIV protease inhibitors. J Med Chem 1995;38:4968-4971.
173. Lam PY, Ru Y, Jadhav PK, Aldrich PE, DeLucca GV, Eyermann CJ, Chang C-H, Emmett G, Holler ER, Daneker WF, Li L, Confalone PN, McHugh RJ, Han Q, Li R, Markwalder JA, Seitz SP, Sharpe TR, Bacheler LT, Rayner MM, Klabe RM, Shum L, Winslow DL, Kornhauser DM, Jackson DA, Erickson-Viitanen S, Hodge CN. Cyclic HIV protease inhibitors: Synthesis, conformational analysis, P2/P2′ structure-activity relationship, and molecular recognition of cyclic ureas. J Med Chem 1996;39:3514-3525.
174. Hodge CN, Aldrich PE, Bacheler LT, Chang CH, Eyermann CJ, Garber S, Grubb M, Jackson DA, Jadhav PK, Korant B, Lam PY, Maurin MB, Meek JL, Otto MJ, Rayner MM, Reid C, Sharpe TR, Shum L, Winslow DL, Erickson-Viitanen S. Improved cyclic urea inhibitors of the HIV-1 protease: Synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450. Chem Biol 1996;3:301-314.
175. Jadhav PK, Woerner FJ, Lam PY, Hodge CN, Eyermann CJ, Man HW, Daneker WF, Bacheler LT, Rayner MM, Meek JL, Erickson-Viitanen S, Jackson DA, Calabrese JC, Schadt M, Chang CH. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: Synthesis, structure-activity relationships, and X-ray crystal structure studies. J Med Chem 1998;41:1446-1455.
176. Bold G, Fassler A, Capraro HG, Cozens R, Klimkait T, Lazdins J, Mestan J, Poncioni B, Rosel J, Stover D, Tintelnot-Blomley M, Acemoglu F, Beck W, Boss E, Eschbach M, Hurlimann T, Masso E, Roussel S, Ucci-Stoll K, Wyss D, Lang M. New aza-dipeptide analogues as potent and orally absorbed HIV-1 protease inhibitors: Candidates for clinical development. J Med Chem 1998;41:3387-3401.
177. Fors KS, Gage JR, Heier RF, Kelly RC, Perrault WR, Wicnienski N. A convergent, scalable synthesis of HIV protease inhibitor PNU-140690. J Org Chem 1998;63:7348-7356.
178. Turner SR, Strohbach JW, Tommasi RA, Aristoff PA, Johnson PD, Skulnick HI, Dolak LA, Seest EP, Tomich PK, Bohanon MJ, Horng MM, Lynn JC, Chong KT, Hinshaw RR, Watenpaugh KD, Janakiraman MN, Thaisrivongs S. Tipranavir (PNU-140690): A potent, orally bioavaible nonpeptidic HIV protease inhibitor of the 5,6-dihydro-4-hydroxy-2-pyrone sulfonamide class. J Med Chem 1998;41:3467-3476.
179. Poppe SM, Slade DE, Chong KT, Hinshaw RR, Pagano PJ, Markowitz M, Ho DD, Mo H, Gorman RR, III, Dueweke TJ, Thaisrivongs S, Tarpley WG. Antiviral activity of the dihydropyrone PNU-140690, a new nonpeptidic human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 1997;41:1058-1063.
180. Robinson BS, Riccardi KA, Gong YF, Guo Q, Stock DA, Blair WS, Terry BJ, Deminie CA, Djang F, Colonno RJ, Lin PF. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000;44:2093-2099.
181. Gong YF, Robinson BS, Rose RE, Deminie C, Spicer TP, Stock D, Colonno RJ, Lin PE In vitro resistance profile of the human immunodeficiency virus type 1 protease inhibitor BMS-232632. Antimicrob Agents Chemother 2000;44:2319-2326.
182. Larder BA, Hertogs K, Bloor S, van den Eynde CH, DeCian W, Wang Y, Freimuth WW, Tarpley G. Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples. AIDS 2000;14:1943-1948.
183. Back NK, van Wijk A, Remmerswaal D, van Monfort M, Nijhuis M, Schuurman R, Boucher CA In vitro tipranavir susceptibility of HIV-1 isolates with reduced susceptibility to other protease inhibitors. AIDS 2000;14:101-102.
184. Rusconi S, La Seta Catamancio S, Citterio P, Kurtagic S, Violin M, Balotta C, Moroni M, Galli M, d'Arminio-Monforte A. Susceptibility to PNU-140690 (tipranavir) of human immunodeficiency virus type 1 isolates derived from patients with multidrug resistance to other protease inhibitors. Antimicrob Agents Chemother 2000;44:1328-1332.
185. Chong KT, Pagano PJ. In vitro combination of PNU-140690, a human immunodeficiency virus type 1 protease inhibitor, with ritonavir against ritonavir-sensitive and resistant clinical isolates. Antimicrob Agents Chemother 1997;41:2367-2773.
186. Wang W, Kollman PA. Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance. Proc Natl Acad Sci USA 2001;98:14937-14942
187. Schubert U, Ott DE, Chertova EN, Welker R, Tessmer U, Princiotta MF, Bennink JR, Krausslich HG, Yewdell JW. Proteasome inhibition interferes with gag polyprotein processing, release, and maturation of HIV-1 and HIV-2. Proc Natl Acad Sci USA 2000;97:13057-13062.